scholarly journals Effects of hepatitis B vaccine boosters in different levels of epidemic areas on anti-HBs-negative children after primary vaccination

2020 ◽  
Author(s):  
Lu Zhu ◽  
Kangli Ye ◽  
Yuanyuan Zheng ◽  
Yan Qiu ◽  
Zikang Wu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine ◽  
Booster Immunization ◽  
Group Iii ◽  
Group I ◽  
Epidemic Area ◽  
High Prevalence ◽  
Different Levels

Introduction. The widespread of hepatitis B virus is a severe global public problem, and the infant hepatitis B vaccine has been proved effective. But the failure of the immune response was reported in studies, and boosters were recommended. There were few studies about the effect of hepatitis B vaccine boosters in different levels of the epidemic area. Hypothesis. Booster immunization is recommended because there may be a lack of immunization in infants vaccinated with the hepatitis B vaccine. In order to verify the effectiveness of booster immunization, this study hypothesized that it worked well in different levels of endemic areas. Aim. To evaluate the effects of hepatitis B vaccine boosters on children from the areas with different prevalence of hepatitis B whose hepatitis B surface antibody (anti-HBs) were negative (<10 mIU ml−1). Methodology. A total of 940 children were initially enrolled in screening; however, 421 were excluded. The participants were divided into three groups according to the different areas they come from: group I, low epidemic area; group II, middle epidemic area; and group III, high epidemic area. In total, 519 subjects were administered three doses of booster hepatitis B vaccine (0–1–6 months, 10 µg). The antibody titre changes were examined at four time points: 1 month after dose 1, 1 month, 1 year and 5 years after dose 3. Results. The protective seroconversion rates in three groups were 96.30, 97.16, 96.63% at 1 month after dose 1, and 100.00, 100.00, 100.00% at 1 month after dose 3, and 97.79, 100.00, 98.50% at 1 year after dose 3, and 90.77, 93.67, 93.59% at 5 years after dose 3 (P>0.05). Conclusions. This study demonstrates that three doses of booster vaccination have a longtime effect, no matter whether it is in low, middle or high prevalence areas in which subjects live.

scholarly journals Long-Term Pertussis-Specific Immunity after Primary Vaccination with a Combined Diphtheria, Tetanus, Tricomponent Acellular Pertussis, and Hepatitis B Vaccine in Comparison with That after Natural Infection

2001 ◽  
Vol 69 (7) ◽  
pp. 4516-4520 ◽  
Author(s):  
Susanna Esposito ◽  
Tiziano Agliardi ◽  
Anna Giammanco ◽  
Giacomo Faldella ◽  
Antonio Cascio ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Natural Infection ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine ◽  
First Year ◽  
Igg Antibody ◽  
Peripheral Blood Mononuclear ◽  
Booster Immunization ◽  
Humoral And Cellular Immunity ◽  
First Year Of Life

ABSTRACT The aim of this study was to compare pertussis-specific humoral and cellular immunity in children 5 years after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine (DTaP-HBV; InfanrixHepB; SmithKline Beecham) with immunity after natural infection. The subjects were 38 children aged 5 to 6 years who received DTaP-HBV at 3, 5, and 11 months of life and 21 subjects of similar ages and sex who acquired pertussis in the first year of life. Immunoglobulin G (IgG) antibody titers againstBordetella pertussis antigens, peripheral blood mononuclear cell-specific proliferation, and the secretion of cytokines were evaluated. After 5 years, only a small proportion of vaccinated and infected children had significant specific concentrations of IgG in serum against all three B. pertussis antigens, and T-cell responses persisted in a minority of subjects. A preferential type 1 cytokine response with the secretion of gamma interferon was observed in the pertussis group, whereas a type 2 skewed response was observed in the vaccinated children; however, the quantitative differences in the cytokines produced by DTaP-HBV and natural infection were minimal. In conclusion, our results show that the immune responses induced by primary pertussis vaccination are qualitatively and quantitatively similar to those seen in children who recovered from natural infection and highlight the need for booster immunization with pertussis vaccines in order to maintain adequate levels of a specific immune response to B. pertussis.

scholarly journals Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24highCD38high Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders

2021 ◽  
Vol 12 ◽  
Author(s):  
Nina Körber ◽  
Laureen Pohl ◽  
Birgit Weinberger ◽  
Beatrix Grubeck-Loebenstein ◽  
Andrea Wawer ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
B Cells ◽  
Hepatitis B ◽  
Booster Vaccination ◽  
Hepatitis B Vaccine ◽  
Third Generation ◽  
Regulatory B Cells ◽  
Expression Levels ◽  
Booster Immunization ◽  
Hepatitis B Vaccines

BackgroundThe cellular mechanisms involved in the lack of protective antibody response after hepatitis B vaccination are still rather unclear. Regulatory B cells (Breg) known as modulators of B-and T-cell responses may contribute to poor vaccine responsiveness. The current study aimed to investigate the role of regulatory B cells (Breg) in hepatitis B vaccine non-responsiveness after immunization with second- or third-generation hepatitis B vaccines.MethodWe performed comparative phenotypic and frequency analysis of Breg subsets (CD24+CD27+ and CD24highCD38high Breg) in second-generation hepatitis B vaccine non-responders (2nd HBvac NR, n = 11) and responders (2nd HBvac R, n = 8) before (d0), on day 7 (d7), and 28 (d28) after booster vaccination. Cryopreserved peripheral blood mononuclear cells were stimulated ex vivo with a combination of CpG, PMA, and Ionomycin (CpG+P/I) and analyzed for numbers and IL-10 expression levels of Breg by flow cytometry-based analyses.ResultsFlow cytometry-based analyses revealed elevated frequencies of CD24+CD27+ Breg at all time points and significantly higher frequencies of CD24highCD38high Breg on d0 (p = 0.004) and 28 (p = 0.012) in 2nd HBvac NR compared to 2nd HBvac R. In parallel, we observed significantly lower levels of CpG+P/I-induced IL-10 expression levels of CD24+CD27+ and CD24highCD38high Breg (d0: p &lt; 0.0001; d7: p = 0.0004; d28: p = 0.0003 and d0: p = 0.016; d7: p = 0.016, respectively) in 2nd HBvac NR compared to 2nd HBvac R before and after booster immunization. Frequencies of CD24+CD27+ and CD24highCD38high Breg significantly decreased after third-generation hepatitis B booster vaccination (d7: p = 0.014; d28: p = 0.032 and d7: p = 0.045, respectively), whereas IL-10 expression levels of both Breg subsets remained stable.ConclusionHere we report significantly higher frequencies of CD24highCD38high Breg in parallel with significantly lower IL-10 expression levels of CD24+CD27+ and CD24highCD38high Breg in 2nd HBvac NR compared to 2nd HBvac R. Anti-HBs seroconversion accompanied by a decrease of Breg numbers after booster immunization with a third-generation hepatitis B vaccine could indicate a positive effect of third-generation hepatitis B vaccines on Breg-mediated immunomodulation in hepatitis B vaccine non-responders.

The effects of booster vaccination of hepatitis B Vaccine on anti-HBV surface antigen negative children 11-15 years after primary vaccination

2011 ◽  
Vol 7 (10) ◽  
pp. 1055-1059 ◽  
Author(s):  
Jun Yao ◽  
Jingjing Ren ◽  
Lingzhi Shen ◽  
Yongdi Chen ◽  
Xiaofeng Liang ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine

scholarly journals STUDY OF IMMUNE RESPONSE AFTER HEPATITIS B VACCINATION IN DOCTORS

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
B.L. Meena ◽  
Nikhil Gandhi ◽  
M.P. Sharma
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Vaccination Status ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Seroprotection Rate

Background: Aim of our study was to evaluate the immune response after hepatitis B vaccination and to determine the duration of protective levels of HBsAb titre in doctors. From our study we concluded that hepatitis-B vaccine gives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required in immunocompetent persons after primary vaccination. Method: In this study total 100 doctors of our institution were included who were vaccinated against hepatitis B. Data were obtained regarding age, sex, weight, height, BMI and duration of vaccination period. Doctors with no prior vaccination or incomplete vaccination or those who took booster vaccination were excluded from this study. Results: The mean titre was observed to be higher in 30 to 34 years of age group (584.42±4.03.21) as compared to age group of less than 25 and greater than 40 years. Moreover, males were observed to have higher mean titre as compared to females. (411.64± 417.27 vs 333.66± 431.49) but not statistically significant.  Similar with age and sex, duration of vaccination status was also not statistically significant. When we compared the  duration of vaccination status with  age group , mean titre was more in ≥30 years of age group as compared to <30 years (younger age groups) but statistically significant relation was observed only with the 1 month to <5 years of duration. Conclusion: From our study we concluded that hepatitis-B vaccinegives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required inimmuno-competent persons after primary vaccination. Keywords: HbsAg titre , HepatitsB vaccine , seroprotection rate.

scholarly journals IMMUNOGENICITY OF LOW-DOSE INTRAMUSCULAR AND INTRADERMAL VACCINATION WITH RECOMBINANT HEPATITIS B VACCINE

1997 ◽  
Vol 39 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Marília Dalva TURCHI ◽  
Celina Maria Turchi MARTELLI ◽  
Maria Lúcia FERRAZ ◽  
Antonio Eduardo SILVA ◽  
Divina das Dores de Paula CARDOSO ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Recombinant Dna ◽  
Standard Dose ◽  
Seroconversion Rate ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Antibody Concentration ◽  
Intradermal Vaccination ◽  
Group I ◽  
Significant Difference

The study is a randomized trial using recombinant DNA vaccine to determine whether an intramuscular 10 µg dose or intradermal 2 µg induces satisfactory anti-HBs levels compared to the standard dose of intramuscular 20 µg. participants were 359 healthy medical and nurse students randomly allocated to one of the three groups: Group I - IM 20 µg; Group II - IM 10 µg; Group III - ID 2 µg at 0, 1 and 6 months. Anti-HBs titres were measured after complete vaccine schedule by ELISA/Pasteur. Baseline variables were similar among groups and side effects were mild after any dose. Vaccinees in the IM-10 µg group had seroconversion rate and geometric mean titre (GMT 2344 IU L-1), not significant different from the IM-20 µg group (GMT 4570 IU L-1). On the contrary, 21.4% of the ID - 2 µg recipients mount antibody concentration below 10 IU L1 and GMT of 91 IU L-1, a statiscally significant difference compared with the standard schedule IM-20 µg (p < 0.001). A three dose regimen of half dosse IM could be considered an appropriate schedule to prevent hepatitis B in young health adults which is of relevance to the expansion of hepatitis B vaccine programme

scholarly journals Long-term protection at 20–31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community

2019 ◽  
Vol 16 (1) ◽  
pp. 16-20
Author(s):  
Jing-Chen Ma ◽  
Zhi-Wei Wu ◽  
Hai-Song Zhou ◽  
Zhao Gao ◽  
Zhi-Yong Hao ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Rural Community ◽  
Primary Vaccination ◽  
Hepatitis B Vaccine

Duration of Response to Intramuscular Versus Low Dose Intradermal Hepatitis B Booster Immunization

1991 ◽  
Vol 12 (4) ◽  
pp. 226-230 ◽  
Author(s):  
W. Paul McKinney ◽  
Susan K. Russler ◽  
Mary M. Horowitz ◽  
Richard J. Battiola ◽  
Martha Bi-Fong Lee
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Cross Sectional ◽  
Booster Immunization ◽  
Booster Vaccine ◽  
Metropolitan County ◽  
Duration Of Response ◽  
Group 2

AbstractObjective:To determine the duration of the immune response to plasma-derived hepatitis B vaccine among healthcare workers responding to booster doses of intradermal (ID) or intramuscular (IM) vaccine in 1986 and those with protective levels of antibody to hepatitis B surface antigen (anti-HBs) in 1986 without booster vaccine. Both groups received a primary hepatitis B vaccine series 24 to 36 months earlier.Design:Cross-sectional follow-up study two years later of an inception cohort defined in 1986.Setting:An academically affiliated metropolitan county hospital.Participants:Group 1: Hospital employees responding to booster doses of hepatitis B vaccine given ID or IM in 1986 due to low anti-HBs levels. Forty-one (82%) of 50 eligible persons were evaluated. Group 2: Persons not receiving booster vaccine in 1986 due to protective levels of anti-HBs. A random sample of 95 persons was drawn from a pool of 152 participants with protective levels in 1986. sixty-five (68%) of 95 contacted persons were restudied.Results:In 1988, 14 (64%) of 22 previous ID responders had anti-HBs levels ≥ 10 milli-international units (mIU)/mL, compared with 17 (89%) of 19 IM responders (p= .055). The 1988 geometric mean titer of IM recipients was 66.4 ±4.5 mIU/mL and of ID recipients was 20.7 ±7.4 (p= .04). None of 65 Group 2 subjects' anti-HBs titers dropped below 10 mIU/mL by 1988.Conclusions:plasma-derived hepatitis B vaccine recipients with anti-HBs levels ≥ 10 mIU/mL at 24 to 36 months after primary immunization are likely to maintain these levels two years later. The diminished durability of the antibody response together with the increased rate of local side effects associated with the ID injection route may limit its applicability as an alternative to using IM booster doses of hepatitis B vaccine.

Sign in / Sign up

Export Citation Format

Share Document